Neoadjuvant treatment in breast cancer Book Section

  


Authors: Wang, R.; Dang, C.
Editors: Urban, C.; Rietjens, M.; El-Tamer, M.; Sacchini, V. S.
Article/Chapter Title: Neoadjuvant treatment in breast cancer
Abstract: Neoadjuvant (preoperative) therapy, initially developed to render primary inoperable tumors, is increasingly being delivered in patients with smaller lesions and particularly in patients with human epidermal growth factor receptor 2 (HER2)-positive and triple-negative breast cancer (TNBC). The neoadjuvant approach offers the advantages of downstaging the tumor and axilla, allowing for less extensive surgery, reducing postoperative complications, and evaluating the efficacy of therapy in vivo. Pathologic complete response (pCR) has been accepted as a primary endpoint in a number of neoadjuvant trials. This chapter provides a summary of the knowledge gained thus far from neoadjuvant trials conducted in breast cancer and discusses the current treatment recommendations and future research and trends. © Springer International Publishing AG, part of Springer Nature 2013, 2019
Keywords: biomarkers; breast cancer; targeted therapy; clinical trials; neoadjuvant; pcr
Book Title: Oncoplastic and Reconstructive Breast Surgery. 2nd ed
ISBN: 978-3-319-62925-4
Publisher: Springer  
Publication Place: Cham, Switzerland
Date Published: 2019-01-01
Start Page: 173
End Page: 178
Language: English
DOI: 10.1007/978-3-319-62927-8_12
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85149553736&doi=10.1007%2f978-3-319-62927-8_12&partnerID=40&md5=1f743523062e9aa5ad67af8ad92b07a4
Notes: Book chapter: 12 -- This chapter can be found under "Part I Basic Principles for Oncoplastic and Reconstructive Breast Surgery" -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Chau Dang
    271 Dang
  2. Virgilio Sacchini
    146 Sacchini
  3. Mahmoud B. El-Tamer
    105 El-Tamer
  4. Rui Wang
    24 Wang
Related MSK Work